메뉴 건너뛰기




Volumn 25, Issue 4, 2014, Pages 289-296

Lipoprotein (a): Gene genie

Author keywords

apolipoprotein (a); cardiovascular disease; genetic and non genetic factors influencing lipoprotein (a)concentration; lipoprotein (a); lipoprotein (a) measurement; therapeutic options

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; LIPOPROTEIN; LIPOPROTEIN A;

EID: 84904172103     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000096     Document Type: Review
Times cited : (14)

References (91)
  • 1
    • 47649091099 scopus 로고
    • A new serum type system in man: The Lp system
    • Berg K. A new serum type system in man: The Lp system. Acta Pathol Microbiol Scand 1963; 59:369-382.
    • (1963) Acta Pathol Microbiol Scand , vol.59 , pp. 369-382
    • Berg, K.1
  • 2
    • 0014779245 scopus 로고
    • Studies of Lp-lipoprotein as a quantitative genetic trait
    • Harvie NR, Schultz JS. Studies of Lp-lipoprotein as a quantitative genetic trait. Proc Natl Acad Sci USA 1970; 66:99-103.
    • (1970) Proc Natl Acad Sci USA , vol.66 , pp. 99-103
    • Harvie, N.R.1    Schultz, J.S.2
  • 3
    • 0023636242 scopus 로고
    • CDNA sequence of human apolipoprotein(a) is homologous to plasminogen
    • McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330:132-137.
    • (1987) Nature , vol.330 , pp. 132-137
    • McLean, J.W.1    Tomlinson, J.E.2    Kuang, W.J.3
  • 4
    • 0027237890 scopus 로고
    • Identification of 34 apolipoprotein( a) isoforms: Differential expression of apolipoprotein(a) alleles between American blacks and whites
    • Marcovina SM, Zhang ZH, Gaur VP, Albers JJ. Identification of 34 apolipoprotein( a) isoforms: Differential expression of apolipoprotein(a) alleles between American blacks and whites. Biochem Biophys Res Commun 1993; 191:1192-1196.
    • (1993) Biochem Biophys Res Commun , vol.191 , pp. 1192-1196
    • Marcovina, S.M.1    Zh, Z.2    Gaur, V.P.3    Albers, J.J.4
  • 5
    • 0023393811 scopus 로고
    • Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma
    • Utermann G, Menzel HJ, Kraft HG, et al. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987; 80:458-465.
    • (1987) J Clin Invest , vol.80 , pp. 458-465
    • Utermann, G.1    Menzel, H.J.2    Kraft, H.G.3
  • 6
    • 67651210632 scopus 로고    scopus 로고
    • Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality
    • Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. J Am Med Assoc 2009; 302:412-423.
    • (2009) J Am Med Assoc , vol.302 , pp. 412-423
    • Erqou, S.1    Kaptoge, S.2    Perry, P.L.3
  • 7
    • 77951637599 scopus 로고    scopus 로고
    • Apolipoprotein(a) isoforms and the risk of vascular disease: Systematic review of 40 studies involving 58,000 participants
    • Erqou S, Thompson A, Di Angelantonio E, et al. Apolipoprotein(a) isoforms and the risk of vascular disease: Systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol 2010; 55:2160-2167.
    • (2010) J Am Coll Cardiol , vol.55 , pp. 2160-2167
    • Erqou, S.1    Thompson, A.2    Di Angelantonio, E.3
  • 9
    • 67149087360 scopus 로고    scopus 로고
    • Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: Results from a GWAS approach
    • Tregouet DA, Heath S, Saut N, et al. Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: Results from a GWAS approach. Blood 2009; 113:5298-5303.
    • (2009) Blood , vol.113 , pp. 5298-5303
    • Tregouet, D.A.1    Heath, S.2    Saut, N.3
  • 10
    • 73549097512 scopus 로고    scopus 로고
    • Genetic variants associated with Lp(a) lipoprotein level and coronary disease
    • Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361:2518-2528.
    • (2009) N Engl J Med , vol.361 , pp. 2518-2528
    • Clarke, R.1    Peden, J.F.2    Hopewell, J.C.3
  • 11
    • 84890500741 scopus 로고    scopus 로고
    • When should we measure lipoprotein (a)?
    • Kostner KM, Marz W, Kostner GM. When should we measure lipoprotein (a)? Eur Heart J 2013; 34:3268-3276.
    • (2013) Eur Heart J , vol.34 , pp. 3268-3276
    • Kostner, K.M.1    Marz, W.2    Kostner, G.M.3
  • 12
    • 84871674237 scopus 로고    scopus 로고
    • Lipoprotein(a): Resurrected by genetics
    • Kronenberg F, Utermann G. Lipoprotein(a): Resurrected by genetics. J Intern Med 2013; 273:6-30.
    • (2013) J Intern Med , vol.273 , pp. 6-30
    • Kronenberg, F.1    Utermann, G.2
  • 14
    • 34648860539 scopus 로고    scopus 로고
    • Genetic defects causing familial hypercholesterolaemia: Identification of deletions and duplications in the LDLreceptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic
    • Tosi I, Toledo-Leiva P, Neuwirth C, et al. Genetic defects causing familial hypercholesterolaemia: Identification of deletions and duplications in the LDLreceptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic. Atherosclerosis 2007; 194:102-111.
    • (2007) Atherosclerosis , vol.194 , pp. 102-111
    • Tosi, I.1    Toledo-Leiva, P.2    Neuwirth, C.3
  • 16
    • 0023940579 scopus 로고
    • Apolipoproteins (a), AI, and B and parental history in men with early onset ischaemic heart disease
    • Durrington PN, Ishola M, Hunt L, et al. Apolipoproteins (a), AI, and B and parental history in men with early onset ischaemic heart disease. Lancet 1988; 1:1070-1073.
    • (1988) Lancet , vol.1 , pp. 1070-1073
    • Durrington, P.N.1    Ishola, M.2    Hunt, L.3
  • 17
    • 79953204259 scopus 로고    scopus 로고
    • Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease
    • Schunkert H, Konig IR, Kathiresan S, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 2011; 43:333-338.
    • (2011) Nat Genet , vol.43 , pp. 333-338
    • Schunkert, H.1    Konig, I.R.2    Kathiresan, S.3
  • 18
    • 0025769197 scopus 로고
    • Lipoprotein (a) and coronary heart disease risk: A nested case-control study of the Helsinki Heart Study participants
    • Jauhiainen M, Koskinen P, EhnholmC, et al. Lipoprotein (a) and coronary heart disease risk: A nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991; 89:59-67.
    • (1991) Atherosclerosis , vol.89 , pp. 59-67
    • Jauhiainen, M.1    Koskinen, P.2    Ehnholm, C.3
  • 19
    • 0027366185 scopus 로고
    • A prospective study of lipoprotein( a) and the risk of myocardial infarction
    • Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein( a) and the risk of myocardial infarction. J Am Med Assoc 1993; 270:2195-2199.
    • (1993) J Am Med Assoc , vol.270 , pp. 2195-2199
    • Ridker, P.M.1    Hennekens, C.H.2    Stampfer, M.J.3
  • 20
    • 0030972032 scopus 로고    scopus 로고
    • Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men
    • Cremer P, Nagel D, Mann H, et al. Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men. Atherosclerosis 1997; 129:221-230.
    • (1997) Atherosclerosis , vol.129 , pp. 221-230
    • Cremer, P.1    Nagel, D.2    Mann, H.3
  • 21
    • 0033675136 scopus 로고    scopus 로고
    • Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: The Caerphilly study
    • Sweetnam PM, Bolton CH, Downs LG, et al. Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: The Caerphilly study. Eur J Clin Invest 2000; 30:947-956.
    • (2000) Eur J Clin Invest , vol.30 , pp. 947-956
    • Sweetnam, P.M.1    Bolton, C.H.2    Downs, L.G.3
  • 22
    • 0036269884 scopus 로고    scopus 로고
    • Lipoprotein (a) as a predictor of coronary heart disease: The PRIME Study
    • Luc G, Bard JM, Arveiler D, et al. Lipoprotein (a) as a predictor of coronary heart disease: The PRIME Study. Atherosclerosis 2002; 163:377-384.
    • (2002) Atherosclerosis , vol.163 , pp. 377-384
    • Luc, G.1    Bard, J.M.2    Arveiler, D.3
  • 23
    • 84893333521 scopus 로고    scopus 로고
    • Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population
    • Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 2014; 63:470-477.
    • (2014) J Am Coll Cardiol , vol.63 , pp. 470-477
    • Kamstrup, P.R.1    Tybjaerg-Hansen, A.2    Nordestgaard, B.G.3
  • 24
    • 84905726369 scopus 로고    scopus 로고
    • Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease
    • doi: 10.1111/joim.12187. [Epub ahead of print]
    • Hopewell JC, Seedorf U, Farrall M, et al. Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease. J Intern Med 2014; doi: 10.1111/joim.12187. [Epub ahead of print]
    • (2014) J Intern Med
    • Hopewell, J.C.1    Seedorf, U.2    Farrall, M.3
  • 25
    • 0030020265 scopus 로고    scopus 로고
    • A comparative study of six commercial lipoprotein(a) assays in seventeen laboratories within the British Isles
    • Mackness MI, Bhatnagar D, Weiringa G, et al. A comparative study of six commercial lipoprotein(a) assays in seventeen laboratories within the British Isles. Ann Clin Biochem 1996; 33:63-70.
    • (1996) Ann Clin Biochem , vol.33 , pp. 63-70
    • MacKness, M.I.1    Bhatnagar, D.2    Weiringa, G.3
  • 26
    • 0031851569 scopus 로고    scopus 로고
    • International Federation of Clinical Chemistry standardization project for the measurement of lipoprotein(a). Phase I. Evaluation of the analytical performance of lipoprotein(a) assay systems and commercial calibrators
    • Tate JR, Rifai N, Berg K, et al. International Federation of Clinical Chemistry standardization project for the measurement of lipoprotein(a). Phase I. Evaluation of the analytical performance of lipoprotein(a) assay systems and commercial calibrators. Clin Chem 1998; 44:1629-1640.
    • (1998) Clin Chem , vol.44 , pp. 1629-1640
    • Tate, J.R.1    Rifai, N.2    Berg, K.3
  • 27
    • 0242331117 scopus 로고    scopus 로고
    • Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent advances and future directions
    • Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent advances and future directions. Clin Chem 2003; 49:1785-1796.
    • (2003) Clin Chem , vol.49 , pp. 1785-1796
    • Marcovina, S.M.1    Koschinsky, M.L.2    Albers, J.J.3    Skarlatos, S.4
  • 28
    • 0035999523 scopus 로고    scopus 로고
    • Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels
    • Scanu AM, Hinman J. Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels. Lipids 2002; 37:439-444.
    • (2002) Lipids , vol.37 , pp. 439-444
    • Scanu, A.M.1    Hinman, J.2
  • 29
    • 84860271201 scopus 로고    scopus 로고
    • Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: Importance of Lp(a)
    • Deshmukh HA, Colhoun HM, Johnson T, et al. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: Importance of Lp(a). J Lipid Res 2012; 53:1000-1011.
    • (2012) J Lipid Res , vol.53 , pp. 1000-1011
    • Deshmukh, H.A.1    Colhoun, H.M.2    Johnson, T.3
  • 30
    • 33645096052 scopus 로고    scopus 로고
    • Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: Report of the thirtyperson/ten-country panel
    • Barter PJ, Ballantyne CM, Carmena R, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: Report of the thirtyperson/ten-country panel. J Intern Med 2006; 259:247-258.
    • (2006) J Intern Med , vol.259 , pp. 247-258
    • Barter, P.J.1    Ballantyne, C.M.2    Carmena, R.3
  • 31
    • 84865308113 scopus 로고    scopus 로고
    • Mechanisms of lipoprotein(a) pathogenicity: Prothrombotic proatherosclerotic or both?
    • Spence JD, Koschinsky M. Mechanisms of lipoprotein(a) pathogenicity: Prothrombotic, proatherosclerotic, or both? Arterioscler Thromb Vasc Biol 2012; 32:1550-1551.
    • (2012) Arterioscler Thromb Vasc Biol , vol.32 , pp. 1550-1551
    • Spence, J.D.1    Koschinsky, M.2
  • 32
    • 84898790907 scopus 로고    scopus 로고
    • Lipoprotein (a), LPA Ile4399Met, and fibrin clot properties
    • Rowland CM, Pullinger CR, Luke MM, et al. Lipoprotein (a), LPA Ile4399Met, and fibrin clot properties. Thromb Res 2014; 133:863-867.
    • (2014) Thromb Res , vol.133 , pp. 863-867
    • Rowland, C.M.1    Pullinger, C.R.2    Luke, M.M.3
  • 33
    • 84897405191 scopus 로고    scopus 로고
    • Inhibition of plasminogen activation by apo(a): Role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a)
    • Romagnuolo R, Marcovina SM, Boffa MB, Koschinsky ML. Inhibition of plasminogen activation by apo(a): Role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a). J Lipid Res 2014; 55:625-634.
    • (2014) J Lipid Res , vol.55 , pp. 625-634
    • Romagnuolo, R.1    Marcovina, S.M.2    Boffa, M.B.3    Koschinsky, M.L.4
  • 34
    • 34547583546 scopus 로고    scopus 로고
    • Lipoprotein (a) and venous thromboembolism in adults: A meta-analysis
    • Sofi F, Marcucci R, Abbate R, et al. Lipoprotein (a) and venous thromboembolism in adults: A meta-analysis. Am J Med 2007; 120:728-733.
    • (2007) Am J Med , vol.120 , pp. 728-733
    • Sofi, F.1    Marcucci, R.2    Abbate, R.3
  • 35
    • 85027946492 scopus 로고    scopus 로고
    • Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis
    • Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis. Arterioscler Thromb Vasc Biol 2012; 32:1732-1741.
    • (2012) Arterioscler Thromb Vasc Biol , vol.32 , pp. 1732-1741
    • Kamstrup, P.R.1    Tybjaerg-Hansen, A.2    Nordestgaard, B.G.3
  • 36
    • 0028174967 scopus 로고
    • Serum Lp(a) lipoprotein concentration and outcome of thrombolytic treatment for myocardial infarction
    • MBewu AD, Durrington PN, Mackness MI, et al. Serum Lp(a) lipoprotein concentration and outcome of thrombolytic treatment for myocardial infarction. Br Heart J 1994; 71:316-321.
    • (1994) Br Heart J , vol.71 , pp. 316-321
    • Mbewu, A.D.1    Durrington, P.N.2    MacKness, M.I.3
  • 37
    • 42049104360 scopus 로고    scopus 로고
    • High levels of inflammatory biomarkers are associated with increased allele-specific apolipoprotein(a) levels in African-Americans
    • Anuurad E, Rubin J, Chiem A, et al. High levels of inflammatory biomarkers are associated with increased allele-specific apolipoprotein(a) levels in African-Americans. J Clin Endocrinol Metab 2008; 93:1482-1488.
    • (2008) J Clin Endocrinol Metab , vol.93 , pp. 1482-1488
    • Anuurad, E.1    Rubin, J.2    Chiem, A.3
  • 38
    • 84861344997 scopus 로고    scopus 로고
    • Association between traditional cholesterol parameters, lipoprotein particle concentration, novel biomarkers and carotid plaques in retired National Football League players
    • Virani SS, Pompeii L, Lincoln AE, et al. Association between traditional cholesterol parameters, lipoprotein particle concentration, novel biomarkers and carotid plaques in retired National Football League players. Atherosclerosis 2012; 222:551-556.
    • (2012) Atherosclerosis , vol.222 , pp. 551-556
    • Virani, S.S.1    Pompeii, L.2    Lincoln, A.E.3
  • 39
    • 0028898083 scopus 로고
    • Extraction of lipoprotein(a), apo B, and apo e from fresh human arterial wall and atherosclerotic plaques
    • Reblin T, Meyer N, Labeur C, et al. Extraction of lipoprotein(a), apo B, and apo E from fresh human arterial wall and atherosclerotic plaques. Atherosclerosis 1995; 113:179-188.
    • (1995) Atherosclerosis , vol.113 , pp. 179-188
    • Reblin, T.1    Meyer, N.2    Labeur, C.3
  • 40
    • 77956495725 scopus 로고    scopus 로고
    • Oxidation-specific biomarkers, lipoprotein( a), and risk of fatal and nonfatal coronary events
    • Tsimikas S, Mallat Z, Talmud PJ, et al. Oxidation-specific biomarkers, lipoprotein( a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol 2010; 56:946-955.
    • (2010) J Am Coll Cardiol , vol.56 , pp. 946-955
    • Tsimikas, S.1    Mallat, Z.2    Talmud, P.J.3
  • 41
    • 77952547617 scopus 로고    scopus 로고
    • Naturally occurring human plasminogen like genetically related apolipoprotein(a) contains oxidized phosphatidylcholine adducts
    • Edelstein C, Pfaffinger D, Yang M, et al. Naturally occurring human plasminogen, like genetically related apolipoprotein(a), contains oxidized phosphatidylcholine adducts. Biochim Biophys Acta 2010; 1801:738-745.
    • (2010) Biochim Biophys Acta , vol.1801 , pp. 738-745
    • Edelstein, C.1    Pfaffinger, D.2    Yang, M.3
  • 42
    • 78650321323 scopus 로고    scopus 로고
    • Oxidized low-density lipoprotein and atherosclerosis
    • Steinberg D, Witztum JL. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30:2311-2316.
    • (2010) Arterioscler Thromb Vasc Biol , vol.30 , pp. 2311-2316
    • Steinberg, D.1    Witztum, J.L.2
  • 44
    • 77951605907 scopus 로고    scopus 로고
    • Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: Collaborative analysis of 32 prospective studies
    • Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: Collaborative analysis of 32 prospective studies. Lancet 2010; 375:1536-1544.
    • (2010) Lancet , vol.375 , pp. 1536-1544
    • Thompson, A.1    Gao, P.2    Orfei, L.3
  • 45
    • 77955270643 scopus 로고    scopus 로고
    • Association of Lp-PLA(2) activity with allele-specific Lp(a) levels in a bi-ethnic population
    • Enkhmaa B, Anuurad E, Zhang W, et al. Association of Lp-PLA(2) activity with allele-specific Lp(a) levels in a bi-ethnic population. Atherosclerosis 2010; 211:526-530.
    • (2010) Atherosclerosis , vol.211 , pp. 526-530
    • Enkhmaa, B.1    Anuurad, E.2    Zhang, W.3
  • 46
    • 0024426378 scopus 로고
    • Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin
    • Karadi I, Romics L, Palos G, et al. Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin. Clin Chem 1989; 35:2121-2123.
    • (1989) Clin Chem , vol.35 , pp. 2121-2123
    • Karadi, I.1    Romics, L.2    Palos, G.3
  • 47
    • 0027050797 scopus 로고
    • Serum lipoprotein (a) in men with proteinuria due to idiopathic membranous nephropathy
    • Short CD, Durrington PN, Mallick NP, et al. Serum lipoprotein (a) in men with proteinuria due to idiopathic membranous nephropathy. Nephrol Dial Transplant 1992; 7 (Suppl 1):109-113.
    • (1992) Nephrol Dial Transplant , vol.7 , Issue.SUPPL. 1 , pp. 109-113
    • Short, C.D.1    Durrington, P.N.2    Mallick, N.P.3
  • 48
    • 0027466745 scopus 로고
    • Serum lipoprotein (a) concentrations in patients undergoing continuous ambulatory peritoneal dialysis
    • Anwar N, Bhatnagar D, Short CD, et al. Serum lipoprotein (a) concentrations in patients undergoing continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1993; 8:71-74.
    • (1993) Nephrol Dial Transplant , vol.8 , pp. 71-74
    • Anwar, N.1    Bhatnagar, D.2    Short, C.D.3
  • 49
    • 0027368658 scopus 로고
    • Serum lipoprotein (a) in renal transplant recipients receiving cyclosporin monotherapy
    • Brown JH, Anwar N, Short CD, et al. Serum lipoprotein (a) in renal transplant recipients receiving cyclosporin monotherapy. Nephrol Dial Transplant 1993; 8:863-867.
    • (1993) Nephrol Dial Transplant , vol.8 , pp. 863-867
    • Brown, J.H.1    Anwar, N.2    Short, C.D.3
  • 50
    • 84904187574 scopus 로고    scopus 로고
    • 1999 Renal disorders
    • Betteridge DJ, Illingworth DR, Arnold SJ, editors London: Arnold Chapter 55
    • Short CD, Durrington PN. 1999 Renal disorders. In: Betteridge DJ, Illingworth DR, Arnold SJ, editors. Lipoproteins in health and disease. London: Arnold; 1999. pp. 943-966. Chapter 55.
    • (1999) Lipoproteins in Health and Disease , pp. 943-966
    • Short, C.D.1    Durrington, P.N.2
  • 51
    • 0031927583 scopus 로고    scopus 로고
    • Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome
    • De Sain-Van Der Velden MG, Reijngoud DJ, Kaysen GA, et al. Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J Am Soc Nephrol 1998; 9:1474-1481.
    • (1998) J Am Soc Nephrol , vol.9 , pp. 1474-1481
    • De Sain-Van Der Velden, M.G.1    Reijngoud, D.J.2    Kaysen, G.A.3
  • 52
    • 0031867582 scopus 로고    scopus 로고
    • Decreased urinary apolipoprotein (a) excretion in patients with impaired renal function
    • Kostner KM, Clodi M, Bodlaj G, et al. Decreased urinary apolipoprotein (a) excretion in patients with impaired renal function. Eur J Clin Invest 1998; 28:447-452.
    • (1998) Eur J Clin Invest , vol.28 , pp. 447-452
    • Kostner, K.M.1    Clodi, M.2    Bodlaj, G.3
  • 53
    • 34047201878 scopus 로고    scopus 로고
    • In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients
    • Frischmann ME, Kronenberg F, Trenkwalder E, et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int 2007; 71:1036-1043.
    • (2007) Kidney Int , vol.71 , pp. 1036-1043
    • Frischmann, M.E.1    Kronenberg, F.2    Trenkwalder, E.3
  • 54
    • 41849143389 scopus 로고    scopus 로고
    • Effects of renal replacement therapy on plasma lipoprotein(a) levels
    • Rosas S, Joffe M, Wolfe M, et al. Effects of renal replacement therapy on plasma lipoprotein(a) levels. Am J Nephrol 2008; 28:361-365.
    • (2008) Am J Nephrol , vol.28 , pp. 361-365
    • Rosas, S.1    Joffe, M.2    Wolfe, M.3
  • 55
    • 84867103661 scopus 로고    scopus 로고
    • Oxidized low-density lipoprotein and lipoprotein(a) levels in chronic kidney disease patients under hemodialysis: Influence of adiponectin and of a polymorphism in the apolipoprotein(a) gene
    • Ribeiro S, Faria Mdo S, Silva G, et al. Oxidized low-density lipoprotein and lipoprotein(a) levels in chronic kidney disease patients under hemodialysis: Influence of adiponectin and of a polymorphism in the apolipoprotein(a) gene. Hemodial Int 2012; 16:481-490.
    • (2012) Hemodial Int , vol.16 , pp. 481-490
    • Ribeiro, S.1    Faria Mdo, S.2    Silva, G.3
  • 56
    • 77955237337 scopus 로고    scopus 로고
    • Lipoprotein(a) and risk of type 2 diabetes
    • Mora S, Kamstrup PR, Rifai N, et al. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem 2010; 56:1252-1260.
    • (2010) Clin Chem , vol.56 , pp. 1252-1260
    • Mora, S.1    Kamstrup, P.R.2    Rifai, N.3
  • 57
    • 21544471214 scopus 로고    scopus 로고
    • Prospective study of lipoprotein(a) as a risk factor for deteriorating renal function in type 2 diabetic patients with overt proteinuria
    • Song KH, Ko SH, Kim HW, et al. Prospective study of lipoprotein(a) as a risk factor for deteriorating renal function in type 2 diabetic patients with overt proteinuria. Diabetes Care 2005; 28:1718-1723.
    • (2005) Diabetes Care , vol.28 , pp. 1718-1723
    • Song, K.H.1    Ko, S.H.2    Kim, H.W.3
  • 58
    • 70350500229 scopus 로고    scopus 로고
    • Association between serum lipoprotein (a) level and progression of nonproliferative diabetic retinopathy in type 2 diabetes
    • Funatsu H, Shimizu E, Noma H, et al. Association between serum lipoprotein (a) level and progression of nonproliferative diabetic retinopathy in type 2 diabetes. Acta Ophthalmol 2009; 87:501-505.
    • (2009) Acta Ophthalmol , vol.87 , pp. 501-505
    • Funatsu, H.1    Shimizu, E.2    Noma, H.3
  • 59
    • 84891779090 scopus 로고    scopus 로고
    • The association between circulating lipoprotein(a) and type 2 diabetes: Is it causal?
    • Ye Z, Haycock PC, Gurdasani D, et al. The association between circulating lipoprotein(a) and type 2 diabetes: Is it causal? Diabetes 2014; 63:332-342.
    • (2014) Diabetes , vol.63 , pp. 332-342
    • Ye, Z.1    Haycock, P.C.2    Gurdasani, D.3
  • 60
    • 84863100136 scopus 로고    scopus 로고
    • High levels of lipoprotein(a) are associated with a lower prevalence of diabetes with advancing age: Results of a cross-sectional epidemiological survey in Gran Canaria, Spain
    • Boronat M, Saavedra P, Perez-Martin N, et al. High levels of lipoprotein(a) are associated with a lower prevalence of diabetes with advancing age: Results of a cross-sectional epidemiological survey in Gran Canaria, Spain. Cardiovasc Diabetol 2012; 11:81.
    • (2012) Cardiovasc Diabetol , vol.11 , pp. 81
    • Boronat, M.1    Saavedra, P.2    Perez-Martin, N.3
  • 61
    • 0031814605 scopus 로고    scopus 로고
    • Insulin and 2-h glucose levels are inversely related to Lp(a) concentrations controlled for LPA genotype
    • Rainwater DL, Haffner SM. Insulin and 2-h glucose levels are inversely related to Lp(a) concentrations controlled for LPA genotype. Arterioscler Thromb Vasc Biol 1998; 18:1335-1341.
    • (1998) Arterioscler Thromb Vasc Biol , vol.18 , pp. 1335-1341
    • Rainwater, D.L.1    Haffner, S.M.2
  • 62
    • 2442497725 scopus 로고
    • Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: Multiplicative interaction of two gene loci associated with premature atherosclerosis
    • Utermann G, Hoppichler F, Dieplinger H, et al. Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: Multiplicative interaction of two gene loci associated with premature atherosclerosis. Proc Natl Acad Sci USA 1989; 86:4171-4174.
    • (1989) Proc Natl Acad Sci USA , vol.86 , pp. 4171-4174
    • Utermann, G.1    Hoppichler, F.2    Dieplinger, H.3
  • 63
    • 0025734425 scopus 로고
    • Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations
    • Mbewu AD, Bhatnagar D, Durrington PN, et al. Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. Arterioscler Thromb 1991; 11:940-946.
    • (1991) Arterioscler Thromb , vol.11 , pp. 940-946
    • Mbewu, A.D.1    Bhatnagar, D.2    Durrington, P.N.3
  • 64
    • 0028936666 scopus 로고
    • The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans
    • Rader DJ, Mann WA, Cain W, et al. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest 1995; 95:1403-1408.
    • (1995) J Clin Invest , vol.95 , pp. 1403-1408
    • Rader, D.J.1    Mann, W.A.2    Cain, W.3
  • 65
    • 2142713910 scopus 로고    scopus 로고
    • Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation
    • Tremblay AJ, Lamarche B, Ruel IL, et al. Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation. J Lipid Res 2004; 45:866-872.
    • (2004) J Lipid Res , vol.45 , pp. 866-872
    • Tremblay, A.J.1    Lamarche, B.2    Ruel, I.L.3
  • 66
    • 0028819191 scopus 로고
    • Increased hepatic secretion of very-low-density-lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: A stable isotope study
    • Cummings MH, Watts GF, Umpleby M, et al. Increased hepatic secretion of very-low-density-lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: A stable isotope study. Atherosclerosis 1995; 113:79-89.
    • (1995) Atherosclerosis , vol.113 , pp. 79-89
    • Cummings, M.H.1    Watts, G.F.2    Umpleby, M.3
  • 67
    • 0030987764 scopus 로고    scopus 로고
    • Lipoprotein Lp(a) excess and coronary heart disease
    • Stein JH, Rosenson RS. Lipoprotein Lp(a) excess and coronary heart disease. Arch Intern Med 1997; 157:1170-1176.
    • (1997) Arch Intern Med , vol.157 , pp. 1170-1176
    • Stein, J.H.1    Rosenson, R.S.2
  • 68
    • 34248150891 scopus 로고    scopus 로고
    • Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)
    • McKenney JM, Jones PH, Bays HE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 2007; 192:432-437.
    • (2007) Atherosclerosis , vol.192 , pp. 432-437
    • McKenney, J.M.1    Jones, P.H.2    Bays, H.E.3
  • 69
    • 84893853699 scopus 로고    scopus 로고
    • Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: An analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)
    • Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: An analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Circulation 2014; 129:635-642.
    • (2014) Circulation , vol.129 , pp. 635-642
    • Khera, A.V.1    Everett, B.M.2    Caulfield, M.P.3
  • 70
    • 76249132266 scopus 로고    scopus 로고
    • Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia
    • Nozue T, Michishita I, Mizuguchi I. Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia. J Atheroscler Thromb 2010; 17:37-44.
    • (2010) J Atheroscler Thromb , vol.17 , pp. 37-44
    • Nozue, T.1    Michishita, I.2    Mizuguchi, I.3
  • 71
    • 0029992875 scopus 로고    scopus 로고
    • Effect of gemfibrozil on levels of lipoprotein[a] in type II hyperlipoproteinemic subjects
    • Jones PH, Pownall HJ, Patsch W, et al. Effect of gemfibrozil on levels of lipoprotein[a] in type II hyperlipoproteinemic subjects. J Lipid Res 1996; 37:1298-1308.
    • (1996) J Lipid Res , vol.37 , pp. 1298-1308
    • Jones, P.H.1    Pownall, H.J.2    Patsch, W.3
  • 72
    • 0027286324 scopus 로고
    • Reduction of Lp(a) plasma levels by bezafibrate
    • Maggi FM, Biasi GM, Catapano AL. Reduction of Lp(a) plasma levels by bezafibrate. Atherosclerosis 1993; 100:127-128.
    • (1993) Atherosclerosis , vol.100 , pp. 127-128
    • Maggi, F.M.1    Biasi, G.M.2    Catapano, A.L.3
  • 73
    • 0024466520 scopus 로고
    • Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid
    • Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989; 226:271-276.
    • (1989) J Intern Med , vol.226 , pp. 271-276
    • Carlson, L.A.1    Hamsten, A.2    Asplund, A.3
  • 74
    • 84861372936 scopus 로고    scopus 로고
    • Extended-release niacin with laropiprant: A review on efficacy, clinical effectiveness and safety
    • Yadav R, France M, Younis N, et al. Extended-release niacin with laropiprant: A review on efficacy, clinical effectiveness and safety. Expert Opin Pharmacother 2014; 13:1345-1362.
    • (2014) Expert Opin Pharmacother , vol.13 , pp. 1345-1362
    • Yadav, R.1    France, M.2    Younis, N.3
  • 75
    • 84855171302 scopus 로고    scopus 로고
    • Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
    • Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255-2267.
    • (2011) N Engl J Med , vol.365 , pp. 2255-2267
    • Boden, W.E.1    Probstfield, J.L.2    Anderson, T.3
  • 76
    • 84904155848 scopus 로고    scopus 로고
    • Results of HPS2-THRIVE presented at American College of Cardiology Scientific Sessions 2013
    • Results of HPS2-THRIVE presented at American College of Cardiology Scientific Sessions 2013. http://www.ctsu.ox.ac.uk/-thrive/.
  • 77
    • 84888090979 scopus 로고    scopus 로고
    • Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: A randomized, double-blind, placebo-controlled trial
    • Thomas GS, Cromwell WC, Ali S, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: A randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2013; 62:2178-2184.
    • (2013) J Am Coll Cardiol , vol.62 , pp. 2178-2184
    • Thomas, G.S.1    Cromwell, W.C.2    Ali, S.3
  • 78
    • 33846151732 scopus 로고    scopus 로고
    • Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia
    • Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007; 356:148-156.
    • (2007) N Engl J Med , vol.356 , pp. 148-156
    • Cuchel, M.1    Bloedon, L.T.2    Szapary, P.O.3
  • 79
    • 78549235583 scopus 로고    scopus 로고
    • Safety of anacetrapib in patients with or at high risk for coronary heart disease
    • Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363:2406-2415.
    • (2010) N Engl J Med , vol.363 , pp. 2406-2415
    • Cannon, C.P.1    Shah, S.2    Dansky, H.M.3
  • 80
    • 84897471477 scopus 로고    scopus 로고
    • Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): A pooled analysis of more than 1,300 patients in 4 phase II trials
    • Raal FJ, Giugliano RP, Sabatine MS, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): A pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol 2014; 63:1278-1288.
    • (2014) J Am Coll Cardiol , vol.63 , pp. 1278-1288
    • Raal, F.J.1    Giugliano, R.P.2    Sabatine, M.S.3
  • 81
    • 78650309921 scopus 로고    scopus 로고
    • Lipid lowering with thyroid hormone and thyromimetics
    • Angelin B, Rudling M. Lipid lowering with thyroid hormone and thyromimetics. Curr Opin Lipidol 2010; 21:499-506.
    • (2010) Curr Opin Lipidol , vol.21 , pp. 499-506
    • Angelin, B.1    Rudling, M.2
  • 82
    • 0028282823 scopus 로고
    • Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations
    • Sacks FM, McPherson R, Walsh BW. Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. Arch Intern Med 1994; 154:1106-1110.
    • (1994) Arch Intern Med , vol.154 , pp. 1106-1110
    • Sacks, F.M.1    McPherson, R.2    Walsh, B.W.3
  • 83
    • 0037458219 scopus 로고    scopus 로고
    • Risk factors and secondary prevention in women with heart disease: The Heart and Estrogen/progestin Replacement Study
    • Vittinghoff E, Shlipak MG, Varosy PD, et al. Risk factors and secondary prevention in women with heart disease: The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2003; 138:81-89.
    • (2003) Ann Intern Med , vol.138 , pp. 81-89
    • Vittinghoff, E.1    Shlipak, M.G.2    Varosy, P.D.3
  • 84
    • 0027787833 scopus 로고
    • Reduction of serum lipoprotein (a) by estrogen in men with prostatic cancer
    • Hiraga T, Shimokawa K, Murase T, Yokoyama M. Reduction of serum lipoprotein (a) by estrogen in men with prostatic cancer. Endocr J 1993; 40:507-513.
    • (1993) Endocr J , vol.40 , pp. 507-513
    • Hiraga, T.1    Shimokawa, K.2    Murase, T.3    Yokoyama, M.4
  • 85
    • 62649151842 scopus 로고    scopus 로고
    • Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy
    • Chasman DI, Shiffman D, Zee RY, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis 2009; 203:371-376.
    • (2009) Atherosclerosis , vol.203 , pp. 371-376
    • Chasman, D.I.1    Shiffman, D.2    Zee, R.Y.3
  • 86
    • 0033607536 scopus 로고    scopus 로고
    • Aspirin reduces apolipoprotein(a) (apo(a)) production in human hepatocytes by suppression of apo(a) gene transcription
    • Kagawa A, Azuma H, Akaike M, et al. Aspirin reduces apolipoprotein(a) (apo(a)) production in human hepatocytes by suppression of apo(a) gene transcription. J Biol Chem 1999; 274:34111-34115.
    • (1999) J Biol Chem , vol.274 , pp. 34111-34115
    • Kagawa, A.1    Azuma, H.2    Akaike, M.3
  • 87
    • 0024448014 scopus 로고
    • Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at reoperation
    • Cushing GL, Gaubatz JW, Nava ML, et al. Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at reoperation. Arteriosclerosis 1989; 9:593-603.
    • (1989) Arteriosclerosis , vol.9 , pp. 593-603
    • Cushing, G.L.1    Gaubatz, J.W.2    Nava, M.L.3
  • 88
    • 61549101898 scopus 로고    scopus 로고
    • Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events
    • Jaeger BR, Richter Y, Nagel D, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009; 6:229-239.
    • (2009) Nat Clin Pract Cardiovasc Med , vol.6 , pp. 229-239
    • Jaeger, B.R.1    Richter, Y.2    Nagel, D.3
  • 89
    • 84890904215 scopus 로고    scopus 로고
    • Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: Prospective observational multicenter study
    • Leebmann J, Roeseler E, Julius U, et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)- hyperlipoproteinemia, and progressive cardiovascular disease: Prospective observational multicenter study. Circulation 2013; 128:2567-2576.
    • (2013) Circulation , vol.128 , pp. 2567-2576
    • Leebmann, J.1    Roeseler, E.2    Julius, U.3
  • 90
    • 84872876060 scopus 로고    scopus 로고
    • Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography
    • Safarova MS, Ezhov MV, Afanasieva OI, et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl 2013; 14:93-99.
    • (2013) Atheroscler Suppl , vol.14 , pp. 93-99
    • Safarova, M.S.1    Ezhov, M.V.2    Afanasieva, O.I.3
  • 91
    • 0030903668 scopus 로고    scopus 로고
    • Lipoprotein A levels after intestinal bypass operation for morbid obesity
    • Boman L, Ericson M. Lipoprotein A levels after intestinal bypass operation for morbid obesity. Obes Surg 1997; 7:125-127.
    • (1997) Obes Surg , vol.7 , pp. 125-127
    • Boman, L.1    Ericson, M.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.